How much revenue did Acticor Biotech generate this year?
Acticor Biotech has achieved a revenue of 61.8 M EUR this year.
Acticor Biotech Revenue 2024
Acticor Biotech Revenue
61.8 M EUR
Ticker
ALACT.PA
ISIN
FR0014005OJ5
WKN
A3C6GM
In 2024, Acticor Biotech's sales reached 61.8 M EUR, a 0% difference from the 0 EUR sales recorded in the previous year.
The Acticor Biotech Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 22.66 | 17,46 |
| 2025e | 4.12 | 96,02 |
| 2024e | 61.8 | 6,40 |
| 2023 | - | - |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | 4.03 | 98,11 |
| 2017 | 8.83 | 96,72 |
| 2016 | 13.84 | 99,59 |
| 2015 | 17.03 | 101,23 |
| 2014 | 19.77 | 98,27 |
| 2013 | 17.54 | 100,00 |
| 2012 | 15.02 | 98,54 |
| 2011 | 10.57 | 97,73 |
| 2010 | 6.7 | 94,78 |
| 2009 | 4.85 | 95,26 |
| 2008 | 2.41 | 90,87 |
Acticor Biotech Revenue, EBIT, Net Income FR0014005OJ5 · A3C6GM
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Acticor Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Acticor Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Acticor Biotech’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Acticor Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Acticor Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Acticor Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Acticor Biotech’s growth potential.
Acticor Biotech Revenue, EBIT and net profit per share
| Date | Acticor Biotech Revenue | Acticor Biotech EBIT | Acticor Biotech Net Income |
|---|---|---|---|
| 2026e | 22.66 M undefined | 17.51 M undefined | 14.28 M undefined |
| 2025e | 4.12 M undefined | -2.06 M undefined | -2.92 M undefined |
| 2024e | 61.8 M undefined | 44.29 M undefined | 36.35 M undefined |
| 2023 | 0 undefined | -17.57 M undefined | -18.64 M undefined |
| 2022 | 0 undefined | -15.12 M undefined | -15.88 M undefined |
| 2021 | 0 undefined | -11.89 M undefined | -12.61 M undefined |
| 2020 | 0 undefined | -7.58 M undefined | -7.65 M undefined |
| 2019 | 0 undefined | -5.17 M undefined | -5.05 M undefined |
| 2018 | 4.03 M undefined | -1.32 M undefined | -5.81 M undefined |
| 2017 | 8.83 M undefined | -1.86 M undefined | -10.37 M undefined |
| 2016 | 13.84 M undefined | -98,880 undefined | -473,170 undefined |
| 2015 | 17.03 M undefined | -1.57 M undefined | -1.36 M undefined |
| 2014 | 19.77 M undefined | 2.22 M undefined | -966,570 undefined |
| 2013 | 17.54 M undefined | 2.67 M undefined | 1.66 M undefined |
| 2012 | 15.02 M undefined | 3.07 M undefined | 2.23 M undefined |
| 2011 | 10.57 M undefined | 2.41 M undefined | 1.67 M undefined |
| 2010 | 6.7 M undefined | 680,000 undefined | 420,000 undefined |
| 2009 | 4.85 M undefined | 130,000 undefined | 0 undefined |
| 2008 | 2.41 M undefined | 110,000 undefined | 80,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 2.41 M EUR | 110,000 EUR | 80,000 EUR |
| 2009 | 4.85 M EUR | 130,000 EUR | 0 EUR |
| 2010 | 6.7 M EUR | 680,000 EUR | 420,000 EUR |
| 2011 | 10.57 M EUR | 2.41 M EUR | 1.67 M EUR |
| 2012 | 15.02 M EUR | 3.07 M EUR | 2.23 M EUR |
| 2013 | 17.54 M EUR | 2.67 M EUR | 1.66 M EUR |
| 2014 | 19.77 M EUR | 2.22 M EUR | -966,570 EUR |
| 2015 | 17.03 M EUR | -1.57 M EUR | -1.36 M EUR |
| 2016 | 13.84 M EUR | -98,880 EUR | -473,170 EUR |
| 2017 | 8.83 M EUR | -1.86 M EUR | -10.37 M EUR |
| 2018 | 4.03 M EUR | -1.32 M EUR | -5.81 M EUR |
| 2019 | 0 EUR | -5.17 M EUR | -5.05 M EUR |
| 2020 | 0 EUR | -7.58 M EUR | -7.65 M EUR |
| 2021 | 0 EUR | -11.89 M EUR | -12.61 M EUR |
| 2022 | 0 EUR | -15.12 M EUR | -15.88 M EUR |
| 2023 | 0 EUR | -17.57 M EUR | -18.64 M EUR |
| 2024e | 61.8 M EUR | 44.29 M EUR | 36.35 M EUR |
| 2025e | 4.12 M EUR | -2.06 M EUR | -2.92 M EUR |
| 2026e | 22.66 M EUR | 17.51 M EUR | 14.28 M EUR |
Acticor Biotech stock margins FR0014005OJ5 · A3C6GM
The Acticor Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acticor Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acticor Biotech.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Acticor Biotech's sales revenue. A higher gross margin percentage indicates that the Acticor Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Acticor Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Acticor Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Acticor Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Acticor Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Acticor Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Acticor Biotech Margin History
| Acticor Biotech Gross margin | Acticor Biotech Profit margin | Acticor Biotech EBIT margin | Acticor Biotech Profit margin |
|---|---|---|---|
| 2026e | 98.11 % | 77.27 % | 63.02 % |
| 2025e | 98.11 % | -50 % | -70.9 % |
| 2024e | 98.11 % | 71.67 % | 58.82 % |
| 2023 | 98.11 % | 0 % | 0 % |
| 2022 | 98.11 % | 0 % | 0 % |
| 2021 | 98.11 % | 0 % | 0 % |
| 2020 | 98.11 % | 0 % | 0 % |
| 2019 | 98.11 % | 0 % | 0 % |
| 2018 | 98.11 % | -32.83 % | -144.12 % |
| 2017 | 96.72 % | -21.05 % | -117.42 % |
| 2016 | 99.59 % | -0.71 % | -3.42 % |
| 2015 | 101.23 % | -9.2 % | -7.96 % |
| 2014 | 98.27 % | 11.21 % | -4.89 % |
| 2013 | 100 % | 15.22 % | 9.46 % |
| 2012 | 98.54 % | 20.44 % | 14.85 % |
| 2011 | 97.73 % | 22.8 % | 15.8 % |
| 2010 | 94.78 % | 10.15 % | 6.27 % |
| 2009 | 95.26 % | 2.68 % | 0 % |
| 2008 | 90.87 % | 4.56 % | 3.32 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 90.87 % | 4.56 % | 3.32 % |
| 2009 | 95.26 % | 2.68 % | 0 % |
| 2010 | 94.78 % | 10.15 % | 6.27 % |
| 2011 | 97.73 % | 22.8 % | 15.8 % |
| 2012 | 98.54 % | 20.44 % | 14.85 % |
| 2013 | 100 % | 15.22 % | 9.46 % |
| 2014 | 98.27 % | 11.21 % | -4.89 % |
| 2015 | 101.23 % | -9.2 % | -7.96 % |
| 2016 | 99.59 % | -0.71 % | -3.42 % |
| 2017 | 96.72 % | -21.05 % | -117.42 % |
| 2018 | 98.11 % | -32.83 % | -144.12 % |
| 2019 | 98.11 % | 0 % | 0 % |
| 2020 | 98.11 % | 0 % | 0 % |
| 2021 | 98.11 % | 0 % | 0 % |
| 2022 | 98.11 % | 0 % | 0 % |
| 2023 | 98.11 % | 0 % | 0 % |
| 2024e | 98.11 % | 71.67 % | 58.82 % |
| 2025e | 98.11 % | -50 % | -70.9 % |
| 2026e | 98.11 % | 77.27 % | 63.02 % |
Acticor Biotech Aktienanalyse
What does Acticor Biotech do?
Acticor Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Acticor Biotech's Sales Figures
The sales figures of Acticor Biotech originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Acticor Biotech’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Acticor Biotech's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Acticor Biotech’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Acticor Biotech stock
How much was the turnover of the company Acticor Biotech compared to the previous year?
The revenue of Acticor Biotech has increased by 0% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Acticor Biotech?
The revenue of Acticor Biotech is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Acticor Biotech measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Acticor Biotech so important for investors?
The revenue of Acticor Biotech is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Acticor Biotech pay?
Over the past 12 months, Acticor Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acticor Biotech is expected to pay a dividend of 0 EUR.
What is the dividend yield of Acticor Biotech?
The current dividend yield of Acticor Biotech is .
When does Acticor Biotech pay dividends?
Acticor Biotech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Acticor Biotech?
Acticor Biotech paid dividends every year for the past 0 years.
What is the dividend of Acticor Biotech?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Acticor Biotech located?
Acticor Biotech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Acticor Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Acticor Biotech from 11/16/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.
When did Acticor Biotech pay the last dividend?
The last dividend was paid out on 11/16/2024.
What was the dividend of Acticor Biotech in the year 2023?
In the year 2023, Acticor Biotech distributed 0 EUR as dividends.
In which currency does Acticor Biotech pay out the dividend?
The dividends of Acticor Biotech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Acticor Biotech
Our stock analysis for Acticor Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acticor Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Acticor Biotech Revenue
- Acticor Biotech Net Income
- Acticor Biotech P/E
- Acticor Biotech P/S
- Acticor Biotech EBIT
- Acticor Biotech Dividend
- Acticor Biotech Stocks
- Acticor Biotech Market capitalization
- Acticor Biotech Debt
- Acticor Biotech Liabilities
- Acticor Biotech Equity
- Acticor Biotech AAQS
- Acticor Biotech Employees
- Acticor Biotech ROE
- Acticor Biotech ROA
- Acticor Biotech ROCE
